Study of ABBV-CLS-628 for adults with polycystic kidney disease
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with ADPKD and your kidney cysts are in classes 1C, 1D, or 1E on a specific Mayo Clinic scan.
- Your kidney function (eGFR) is between 30 and 90 mL/min/1.73 m².
- Not currently taking any other treatments for ADPKD that are not approved or involved lifestyle changes.
- No other serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
This study tests an investigational drug (BI 764198) in adults and teens with different types of kidney disease. The goal is to see if the drug can help slow kidney damage. You may be able to join if your kidney function is at a certain level, you are on stable blood pressure medications, and you haven't had recent strong immune treatments.
This study enrolls adults with autosomal dominant polycystic kidney disease (ADPKD) to better understand the disease and its related changes in the body. It may help researchers find improved ways to track the condition and support future treatments.
Hear when a new Autosomal Dominant Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.